Public-Private Partnerships for Gene Therapies: What Does the Public Get?
Join us on听Friday, January 10 at听12pm ET听for听ELSI听Friday听Forum: Public-Private Partnerships for Gene Therapies: What Does the Public Get?,听听with speakers:
-
John Conley, JD, PhD, University of North Carolina at Chapel Hill School of Law
-
Eva Winkler, Prof, Dr.med., Dr.phil., Section for Translational Medical Ethics,听National Center for Tumor Diseases (NCT) Heidelberg
-
Moderated by Philip J. Brooks, PhD, Division of Rare Diseases Research Innovation, National Center for Advancing Translational Sciences (NCATS)
Publicly-funded researchers frequently transfer their gene therapy and gene-editing medical research to venture capital-funded startups for clinical development. In tandem, the public sector financial crisis in many countries has meant that partnerships with commercial entities are used to leverage the full potential of publicly-held genomic data. However, public-private partnerships in the genomics translational pipeline raise several key questions. Which benefits should be returned to the public, if any? How should products be priced? How should data be managed? Does involvement of publicly funded scientists in the commercial sector conflict with the commitment to deliver societally beneficial innovation?